Multiple myeloma with paraneoplastic leucocytoclastic vasculitis.
Jain
P
P
Kumar
P
P
Parikh
P M
PM
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D010257:Paraneoplastic Syndromes / Q000175:diagnosis* / Q000209:etiology / Q000276:immunology / Q000628:therapy; D017445:Skin Diseases, Vascular / Q000175:diagnosis* / Q000209:etiology / Q000276:immunology / Q000628:therapy; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000175:diagnosis* / Q000209:etiology / Q000276:immunology / Q000628:therapy; D014750:Vincristine / Q000627:therapeutic use; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D007074:Immunoglobulin G; D014750:Vincristine; D000077211:Zoledronic Acid; D003907:Dexamethasone; D004317:Doxorubicin